Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction.

Autor:	Yehya A; Advanced Heart Failure Center, Sentara Heart Hospital, Norfolk, Virginia, USA. Electronic address: amin.yehya@yahoo.com., Lopez J; Division of Cardiovascular Disease, University of Miami Miller School of Medicine, JFK Hospital, Atlantis, Florida, USA., Sauer AJ; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA., Davis JD; Division of Cardiology, San Francisco General Hospital, Department of Medicine, University of California, San Francisco, California, USA., Ibrahim NE; Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Tung R; The University of Arizona College of Medicine-Phoenix, Banner-University Medical Center, Phoenix, Arizona, USA., Bozkurt B; Division of Cardiology, Baylor College of Medicine, Houston, Texas, USA., Fonarow GC; UCLA Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, California, USA., Al-Khatib SM; Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Jazyk:	angličtina
Zdroj:	JACC. Heart failure [JACC Heart Fail] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.
DOI:	10.1016/j.jchf.2024.09.014
Abstrakt:	Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with reduced ejection fraction (HFrEF). The landmark studies leading to the current guideline recommendations preceded the 4 pillars of guideline-directed medical therapies (GDMTs). Therefore, some have questioned the role of ICDs for primary prevention in current clinical practice. In this paper, the authors provide an overview of the current ICD recommendations, including the instrumental clinical trials, the risk of SCD as observed in clinical trials vs real-world scenarios, disparities in ICD use among different patient populations, the impact of contemporary GDMT on outcomes, and ongoing and future trials and methodologies to help identify patients who are at an increased risk of SCD and who may benefit from an ICD. The authors also propose a pragmatic guidance for clinicians when they engage in the shared decision-making discussions for primary ICD implantation. Competing Interests: Funding Support and Author Disclosures Dr Yehya has received speaking honoraria and consulting fees from Bayer, Merck, Novo Nordisk, AstraZeneca, and scPharmaceuticals. Dr Sauer has received research funding and consulting or speaking honoraria from Amgen, Abbott, Bayer, Boston Scientific, CSL Vifor, AstraZeneca, Impulse Dynamics, Fire1, uLink, Story Health, General Prognostics, Acorai, Edwards Lifesciences, Rivus, Pfizer, 35Pharma, and Regeneron; and owns stock in ISHI, a privately held digital health company. Dr Bozkurt has received consulting fees from Abbott, Abiomed, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson and Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, and Vifor. Dr Fonarow has received consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Eli Lilly, Johnson and Johnson, Medtronic, Merck, Novartis, and Pfizer. Nasrien Ibrahim has received consulting fees from Applied Therapeutics and Cytokinetics. Dr Tung has received speaking honoraria and consulting fees from Medtronic, Abbott, Biotronik, Boston Scientific. All other authors have no relationships relevant to the contents of this paper to disclose. (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu